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The brain‑derived neurotrophic factor (BDNF) protein is essential for neuronal development. Val66Met 
(rs6265) is a functional polymorphism at codon 66 of the BDNF gene that affects neuroplasticity and 
has been associated with cognition, brain structure and function. The aim of this study was to clarify 
the relationship between BDNF Val66Met polymorphism and neuronal oscillatory activity, using 
the electroencephalogram (EEG), in a normative cohort. Neurotypical (N = 92) young adults were 
genotyped for the BDNF Val66Met polymorphism and had eyes open resting‑state EEG recorded 
for four minutes. Focal increases in right fronto‑parietal delta, and decreases in alpha‑1 and right 
hemispheric alpha‑2 amplitudes were observed for the Met/Met genotype group compared to Val/Val 
and Val/Met groups. Stronger frontal topographies were demonstrated for beta‑1 and beta‑2 in the 
Val/Met group versus the Val/Val group. Findings highlight BDNF Val66Met genotypic differences in 
EEG spectral amplitudes, with increased cortical excitability implications for Met allele carriers.
Brain-derived neurotrophic factor (BDNF) is an essential protein widely expressed in the  brain1 that is critical 
for neurogenesis and differentiation, synaptic plasticity, and cognition (learning, memory, executive function-
ing)2. The BDNF Val66Met (rs6265) polymorphism is a functional polymorphism in the BDNF gene where a 
valine (Val) to methionine (Met) amino acid substitution at codon  663 occurs. The BDNF Val66Met polymor-
phism causes impaired activity-dependent secretion of BDNF in individuals carrying one or more copies of the 
Met allele relative to non-Met carriers (Val/Val genotype)4. The Met allele has been associated with cognitive 
impairment, particularly  memory5, reduced hippocampal  volume6, increased risk of  depression7,8, anxiety-related 
 behaviors9, neurodegenerative  disorders10, particularly Alzheimer’s disease (AD), and psychiatric disorders such 
as  schizophrenia11. Due to its neuroprotective effects, BDNF has also been implicated as a potential therapeutic 
agent for  AD12.
The BDNF Val66Met polymorphism has been linked to memory function in healthy adults, with young adult 
Met carriers (Val/Met, Met/Met) exhibiting poorer episodic memory performance (as measured by the Repeat-
able Battery for the Assessment of Neuropsychological Status [RBANS]) than their Val homozygous  peers12. 
Young adults (aged 24.0 ± 0.8 years) heterozygous for the Val/Met genotype also showed lower working memory 
ability (as measured by a 2-back task) when compared to the Val/Val  homozygotes4.
There is also an established relationship between the BDNF Val66Met polymorphism, white and grey matter 
structural alterations, and functional hemodynamic brain changes in healthy  individuals3,13. Structural mag-
netic resonance imaging (MRI) studies have reported a reduction in the volume of temporal and occipital 
lobe grey  matter14,  hippocampus15,  amygdala16, and prefrontal  cortex15 in healthy Met carriers (Val/Met, Met/
Met) compared to Val/Val homozygotes of the BDNF Val66Met polymorphism. Healthy middle-aged adults 
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(46.4 ± 6.8 years) carrying one or more copies of the Met allele showed lower hemodynamic responses (blood 
oxygen level dependent [BOLD]) in the right superior frontal gyrus and the middle occipital gyrus than the 
non-Met carriers (Val/Val genotype, aged 49.1 ± 4.1 years) during n-back working memory tasks, as measured by 
functional MRI (fMRI)17. Alterations in hippocampal and lateral prefrontal activation in Met/Met homozygotes, 
and a localised reduction in hippocampal grey matter volume compared to Val carriers (Val/Met and Val/Val 
genotypes), as measured by fMRI and structural MRI (respectively) have also been  demonstrated18.
Resting state electroencephalographic (EEG) spectral activity provides a measurement of the intrinsic activ-
ity of neuronal populations and large-scale neuronal networks, and is linked to a range of factors such as cog-
nitive function, task performance, clinical phenotypes, and arousal states. Several studies have explored the 
effects of the BDNF Val66Met polymorphism on waking resting state EEG activity in adults across several 
conditions. In healthy adults (aged 24.0 ± 0.8 years), EEG alpha power (9.75–11.75 Hz) in prolonged (40 h) 
wakefulness was roughly doubled in Val/Val homozygotes compared to the heterozygous counterpart (Val/Met 
genotypes)4. In another study of participants assessed for trait depression, homozygous Met allele carriers (aged 
36.9 ± 12.6 years) exhibited higher delta (1.5–3.5 Hz) and theta (4.0–7.5 Hz) power, and lower alpha (8–13 Hz) 
and beta (14.5–30 Hz) power in both eyes-open (EO) and eyes-closed (EC) resting-state EEG, relative to partici-
pants homozygous for the Val  allele7; this Met/Met-related modulation of neuronal activity was associated with 
trait depression. Similarly, another study found a negative correlation between parietal-occipital alpha power 
(8–13 Hz) and depression severity, which was maximal in the Met/Met genotype  group8. To date, all prior stud-
ies investigating the effects of the BDNF Val66Met polymorphism on EEG frequency spectra have done so in a 
clinical context (e.g., sleep deprivation, depression), with no studies characterising BDNF Val66Met genotypic 
differences in EEG spectra in a neurotypical context. It should be noted that a range of other studies have inves-
tigated BDNF Val66Met polymorphism-related differences in EEG-derived event-related potentials (ERPs)18–20, 
EEG recorded during  sleep4, or under general  anesthetic21, magnetoencephalography (MEG)22 and non-invasive 
brain stimulation such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation 
(tDCS)20,23–25; these are beyond the scope of the current study and will not be reviewed further.
The aim of this study was to further understand the relationship between variants of the BDNF Val66Met 
polymorphism and EEG brain activity in neurotypical young adults. It was hypothesised that compared to the 
Val/Val genotype group, individuals carrying one or more copies of the Met allele (Met/Met and Val/Met geno-
type groups) would have greater delta and theta, and lower alpha  activity4,7, and that the Val/Met genotype group 
would have greater beta activity than the Met/Met genotype  group7. To improve comparability with previous 
EEG studies and test key  hypotheses7,8,18,19, the three genotype groups were compared, rather than testing Met 
allele carriers versus non-Met carriers.
Materials and methods
Eligibility criteria. Individuals enrolled in the School of Psychology at the University of Wollongong were 
recruited to participate in the study in return for course credit. Written informed consent was obtained, fol-
lowed by completion of a demographic and screening questionnaire. Saliva samples were collected using the 
OrageneDNA collection kit (DNA Genotek, Canada), and EEG measures were recorded. Participants were 
instructed to refrain from consuming psychoactive substances for at least 12 h prior to EEG testing, and from 
consuming tea, coffee, alcohol, and cigarettes for at least 2 h prior to saliva collection. Eligibility criteria were 
self-reported, and included no prior use of psychotropic/central nervous system medication, no neurological or 
psychiatric illnesses, normal hearing, and normal or corrected-to-normal vision. Ethical approval for this study 
was obtained from the University of Wollongong and Illawarra and Shoalhaven Local Health District Health and 
Medical Human Research Ethics Committee. This research was conducted in accordance with the International 
Ethical Guidelines for Biomedical Research Involving Human Subjects prepared by the Council for International 
Organisations of Medical Sciences (CIOMS) in collaboration with the World Health Organisation (WHO), and 
the Australian National Statement on Ethical Conduct in Research Involving Humans. Written informed con-
sent was obtained from all study participants, and participants were free to withdraw at any time without penalty.
DNA extraction and Val66Met genotyping. As per Steiner et al.20, following sample collection, saliva 
was stored at room temperature until DNA was extracted as per the manufacturer’s recommendations (Oragene, 
Canada). After extraction, DNA samples were quantified using a NanoDrop ND-1000, and stored at − 20 °C. 
High-throughput SNP genotyping was performed using the MassARRAY genotyping assay (Sequenom, Inc., 
San Diego, CA), with the analysis performed by matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS). Extension primer design, and selection were performed using MassARRAY 
Designer Software (Sequenom, Inc., San Diego, CA). Control samples were run in parallel with the tested sam-
ples (on each plate), allowing for accurate evaluation and quality control checks of each of the steps involved 
(PCR amplification, Shrimp Alkaline Phosphatase treatment, extension PCR, nano-dropping to check product 
concentrations, nano-dispensing of samples onto the chip, and instrument performance). Each participant was 
genotyped as homozygous Val/Val (GG), heterozygous Val/Met (GA), or homozygous Met/Met (AA)20.
EEG acquisition and processing. As per Steiner et al., 2018, participants were seated in an air-condi-
tioned room 600–800 mm in front of a 19″ Dell LCD monitor, and completed an electrooculogram (EOG)/EEG 
calibration  task21. Participants were then instructed to fixate on a 10 × 10 mm gray cross centered on a black 
background, while EO resting EEG activity was recorded for 4 min.
Continuous EEG data were recorded DC–30 Hz with a Neuroscan Synamps 2 digital signal-processing system 
and Neuroscan 4.3.1 Acquire software (Compumedics, Charlotte, NC) from 30 scalp sites (Fp1, Fp2, F7, F3, Fz, 
F4, F8, FT7, FC3, FCz, FC4, FT8, T7, C3, Cz, C4, T8, TP7, CP3, CPz, CP4, TP8, P7, P3, Pz, P4, P8, O1, Oz, O2), 
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grounded by an electrode located midway between Fp1, Fp2, and Fz. Two recording setups were combined to 
obtain data: one used electrode caps with tin electrodes referenced to A1 and included A2 as a separate active 
channel for offline re-referencing (N = 59), sampled at 1000 Hz; the second setup was recorded using sintered 
Ag/AgCl electrodes referenced to the nose and recording M1 and M2 as active channels (N = 33) sampled at 
2000 Hz. In both setups, EOG was recorded using tin cup electrodes placed 2 cm above and below the left eye 
for vertical movements, and on the outer canthus of each eye for horizontal movements. Impedance was < 10 
kΩ for all electrodes.
EEG data were corrected for all eye-movement types using the Revised Aligned-Artifact Average (RAAA) 
EOG Correction  Program21, which removes the EOG voltage contribution from the EEG using a regression-based 
approach (with coefficients based on the calibration task run for each participant). Data were re-referenced to 
digitally linked ears (N = 59) or mastoids (N = 33) and extracted offline using Neuroscan Edit software (Com-
pumedics, Charlotte, NC); the dataset recorded at 2000 Hz was resampled to 1000 Hz. The 4-min of data were 
segmented into 2000 ms epochs, each DC-corrected by baselining across the entire epoch, and any epochs 
containing artifact exceeding ± 75 μV were rejected. A visual inspection was conducted to further remove arti-
fact-contaminated trials, and interpolate channels containing excessive artifact (> 70% epochs retained) with 
unaffected data from immediately surrounding sites. Data were quantified in MATLAB and EEGLAB (Version 
14.0.0b). For each subject and epoch, spectral amplitudes were computed using Discrete Fourier Transforms 
with a 10% Hanning window; correction for the window was subsequently applied. Frequency data from 0.0 
to 29.5 Hz were extracted with a resolution of 0.5 Hz before averaging across epochs. The spectral band ampli-
tudes were calculated by summing the activity across the frequency bins for delta: 0.5–3.5 Hz; theta: 4.0–7.5 Hz; 
alpha-1: 8.0–10.5 Hz; alpha-2: 11.0–13.5 Hz; beta-1: 14.0–20.5 Hz; and beta-2: 21.0–29.0 Hz. This resulted in 
one datapoint for each subject, electrode, and band.
Statistical analyses. Mixed-model 3 × 3 × 3 MANOVAs with the within-subjects factors of sagittal (frontal, 
central, parietal) and coronal topographies (left, midline, right) and between-subjects factor of genotype (Val/
Val, Val/Met, Met/Met) were conducted for each EEG band using IBM SPSS Statistics, v22. To facilitate topo-
graphic analyses of EEG bands, data were pooled across the 30 electrodes to form 9 regions: frontal-left (FL: 
Fp1, F3, FC3,F7, FT7), frontal-midline (FM: Fz, FCz), frontal-right (FR: Fp2, F4, FC4, F8, FT8); central-left (CL: 
C3, CP3, T7, TP7), central-midline (CM: Cz, CPz), central-right (CR: C4, CP4, T8, TP8); posterior-left (PL: 
P3, P7, O1), posterior-midline (PM: Pz, Oz), posterior-right (PR: P4, P8, O2). These regions are represented 
diagrammatically in Fig. 1. EEG band topographies from these 9 regions (FL, FM, FR, CL, CM, CR, PL, PM, 
PR) were compared using planned orthogonal contrasts within each plane – sagittal: frontal (F) versus poste-
rior (P) regions, and central (C) versus the mean of frontal and posterior regions (F/P); and coronal: left (L) 
versus right (R), and midline (M) versus the mean of left and right regions (L/R). Genotypes were compared 
using planned simple contrasts: Val/Val versus Met/Met, Val/Val versus Val/Met, and Val/Met versus Met/Met. 
All F-tests reported were one-tailed (because directional hypotheses were specified) and had (1, 89) degrees of 
freedom unless otherwise specified; α was set at 0.05 for all tests. It should also be noted that as this paper details 
results for multiple dependent measures (e.g., EEG frequency bands), the frequency of Type I errors increases. 
However, this increase in frequency of Type I errors cannot be controlled by adjusting α-levels, because the prob-
ability of Type I error remains the  same26. 
eLORETA (exact low resolution brain electromagnetic tomography,  v2017022027,28 was used to examine 
the sources of each EEG frequency band. Source localisation was conducted on the grand mean EEG band 
Figure 1.  Regions of interest to facilitate topographic analyses of EEG bands.
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amplitudes with the aim of complementing the statistical analyses of their scalp topography and assist with the 
neurobiological interpretation of the results.
Ethics approval. Ethics approval for this study was requested and approved through the University of 
Wollongong and Illawarra and Shoalhaven Local Health District Health and Medical Human Research Ethics 
Committee. This research was conducted in accordance with the International Ethical Guidelines for Biomedi-
cal Research Involving Human Subjects prepared by the Council for International Organisations of Medical 
Sciences (CIOMS) in collaboration with the World Health Organisation (WHO), and the Australian National 
Statement on Ethical Conduct in Research Involving Humans.
Consent to participate. All participants were provided with a copy of the participant information sheet 
and consent form, and written informed consent was obtained from all participants prior to ocmmencing data 
collection.
Consent for publication. All participants consented to the publication of their data in the deidentified 
aggregate form in which it is presented.
Results
Genotype. The sample included 92 undergraduate students (Mage = 21.4, SD = 5.0 years, 67% female, major-
ity Caucasian ethnicity). Table 1 shows that there were no significant differences in age, gender, lab setup (as the 
data were recorded in two different labs; see Sect. 2.3), or number of epochs accepted between the three BDNF 
Val66Met genotype groups (all p > 0.05). Data were normally distributed based on the skewness and kurtosis of 
histogram plots. Genotype breakdowns across the sample were as follows: Val/Val n = 61 (66.3%); Val/Met n = 25 
(27.2%); Met/Met n = 6 (6.5%). The allele frequency for G (encodes Val) was 74.6%, and A (encodes Met) was 
25.4%. This did not differ from the Hardy–Weinberg equilibrium (χ2 = 0.64, p = 0.726).
EEG. EEG spectral data for the two lab setups across the 30 scalp sites and six EEG bands were highly similar 
(r(180) = 0.80, p < 0.001); thus data were pooled and not treated separately for any further analyses. EEG spectra 
for each of the three BDNF Val66Met genotype groups at Fz, Cz, and Pz are shown in Fig. 2. The MANOVA out-
comes that were statistically significant for each of the EEG bands are summarised below in text with the statisti-
cal outcomes in Table 2. Note that some of the pairs of greater than (>) and/or less than (<) sign entries in Table 2 
are reversed in their text descriptions. This utilises the logical equivalence of such pair reversals, facilitating the 
tabulation of band differences in each effect (e.g., C < F/P × M > L/R is logically equivalent to C > F/P × M < L/R). 
Delta amplitudes were greater frontally than parietally (F > P: F = 9.962, p = 0.002, ηp2 = 0.10), larger on the right 
than the left (L < R: F = 6.892, p = 0.010, ηp2 = 0.07), and in the midline compared with the hemispheres (M > L/R: 
F = 25.209, p < 0.001, ηp2 = 0.22). Frontal amplitudes were greatest in the midline (F > P × M > L/R: F = 23.294, 
p < 0.001, ηp2 = 0.21), and fronto-posterior amplitudes were greatest on the right (C < F/P × L < R: F = 19.299, 
p < 0.001, ηp2 = 0.18). As shown in Fig. 3 the right hemispheric enhancement was larger for the Met/Met genotype 
group compared with the Val/Val and Val/Met genotype groups (Val/Val < Met/Met × L < R: F = 7.101, p = 0.009, 
ηp2 = 0.07; Val/Met < Met/Met × L < R: F = 8.732, p = 0.004, ηp2 = 0.09), as was the right fronto-posterior enhance-
ment (Val/Val < Met/Met × C < F/P × L < R: F = 6.098, p = 0.015, ηp2 = 0.06; Val/Met < Met/Met × C < F/P × L < R: 
F = 8.223, p = 0.005, ηp2 = 0.08). To improve readability, statistical effects are omitted from the remaining text; 
please refer to Table 2 for this information.
Theta amplitudes showed frontal (p < 0.001) as well as midline enhancements (p < 0.001); these effects inter-
acted, with frontal amplitudes greatest in the midline (p < 0.001). Theta was greater on the right fronto-posteriorly 
(p = 0.006). There were no main effects or interactions involving BDNF Val66Met genotype.
Alpha-1 amplitudes were largest in the posterior region (p < 0.001), in the right hemisphere (p = 0.029) and in 
the midline (p < 0.001), with the midline enhancement largest frontally (p < 0.001). Alpha-1 was smaller centrally 
on the right (p = 0.001). This right-central reduction in alpha-1 was greater for Met/Met than for both Val/Val 
and Val/Met genotype groups (p = 0.027, p = 0.031).
Alpha-2 showed a parietal topography (p < 0.001) that was greatest on the right (p = 0.009). There was a 
midline enhancement (p = 0.005) that was largest frontally (p < 0.001) and centrally (p < 0.001); central alpha-2 
was larger in the left than right hemisphere (p = 0.026). The Met/Met group showed a reduction in this left hemi-
spheric enhancement observed for both Val/Val and Val/Met genotype groups (p = 0.013, p = 0.014).
For Beta-1, amplitudes were maximal in the parietal region (p < 0.001), and fronto-parietally compared to 
centrally (p = 0.019); this was greatest in the midline (p = 0.044). Frontally, the interaction was largest in the 
Table 1.  Age, gender, lab set-up, and epochs accepted information for BDNF Val66Met genotype groups.
Val/Val (n = 61) Val/Met (n = 25) Met/Met (n = 6) Statistical difference
Age, years 21.37 ± 5.11 21.69 ± 5.13 20.69 ± 3.19 F(2,91) = 0.10, p = 0.901
Gender Female n (% of total) 41 (67.21) 17 (68.00) 4 (66.67) χ2(2) = 0.01, p = 0.996
Lab Setups A = 20, B = 41 A = 10, B = 15 A = 3, B = 3 χ2(2) = 1.01, p = 0.603
Epochs accepted n 85.62 ± 21.44 84.48 ± 23.04 84.83 ± 26.06 F(2,91) = 0.03, p = 0.970
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midline compared to the right and left hemispheres (p < 0.001). The Val/Met genotype group showed greater 
frontal beta-1 activity compared to the Val/Val genotype group (p = 0.008).
Beta-2 was enhanced frontally (p = 0.001) and fronto-parietally (p < 0.001), with the frontal enhancement 
being greatest in the midline (p = 0.022). As with beta-1, beta-2 amplitudes were larger frontally in the Val/Met 
genotype group compared to the Val/Val genotype group (p = 0.038).
Source localisation. The grand mean eLORETA source plots for each of the EEG bands are illustrated in 
Fig. 4. The major structural sources and the dominant five Brodmann areas (BAs) involved for each band are 
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detailed below. For delta, this was the superior and middle frontal gyrus (BA 9, 10, 11), inferior frontal gyrus 
(BA 47), and the anterior cingulate (BA 32). Theta was maximal in the cingulate gyrus (BA 6, 24, 32) and medial 
frontal gyrus (BA 8, 9). Alpha-1 was largest in the cuneus (BA 17, 18, 19), the paracentral lobule (BA 4), and 
the postcentral gyrus (BA 5). Alpha-2 was also maximal in the cuneus (BA 18, 19) the paracentral lobule (BA 
4), and the postcentral gyrus (BA 3, 5). The five major sources active for beta-1 were the cuneus (BA 17, 18, 19), 
the superior frontal gyrus (BA 9), and the middle frontal gyrus (BA 10). The greatest sources for beta-2 were the 
superior frontal gyrus (BA 9, 10), the middle frontal gyrus (BA 11, 46), and the inferior frontal gyrus (BA 47).
Discussion
This study explored the differences in resting state EEG spectral activity associated with the BDNF Val66Met 
polymorphism in healthy young adults. Hypotheses were partially confirmed, with the Met/Met genotype group 
showing enhanced fronto-parietal-right delta and attenuated right-centro-parietal alpha-1 and left hemispheric 
alpha-2 activity compared to both Val/Val and Val/Met genotype groups; unexpectedly, theta was unaffected by 
genotype  status4,7. Counter to expectations, greater frontal beta-1 and beta-2 amplitudes were observed in the 
Val/Met genotype group compared to the Val/Val genotype  group7. Findings have implications for increased 
cortical excitability for Met allele carriers that are discussed further below.
Right hemispheric and fronto-parieto-right delta amplitudes were greater for the Met/Met group compared to 
both homozygous Val/Val and heterozygous Val/Met genotypes. These genotype-related topographic differences 
Table 2.  Statistically significant (p < .05) outcomes from the mixed-model MANOVAs.
Band Effect F p ηp2
Delta
F > P 9.962 .002 .10
L < R 6.892 .010 .07
M > L/R 25.209  < .001 .22
F > P × M > L/R 23.294  < .001 .21
C < F/P × L < R 19.299  < .001 .18
Val/Val < Met/Met × L < R 7.101 .009 .07
Val/Met < Met/Met × L < R 8.732 .004 .09
Val/Val < Met/Met × C < F/P × L < R 6.098 .015 .06
Val/Met < Met/Met × C < F/P × L < R 8.223 .005 .08
Theta
F > P 30.581  < .001 .25
M > L/R 46.922  < .001 .34
F > P × M > L/R 139.727  < .001 .61
C < F/P × L < R 7.858 .006 .08
Alpha-1
F < P 13.739  < .001 .13
L < R 4.936 .029 .05
M > L/R 18.515 .000 .17
F > P × M > L/R 43.829  < .001 .32
C < F/P × L < R 11.423 .001 .11
Val/Val < Met/Met × C < F/P × L < R 5.034 .027 .05
Val/Met < Met/Met × C < F/P × L < R 4.805 .031 .05
Alpha-2
F < P 24.126  < .001 .21
L < R 7.137 .009 .07
M > L/R 8.388 .005 .08
F > P × M > L/R 39.276  < .001 .30
C > F/P × L > R 5.141 .026 .05
C > F/P × M > L/R 15.351  < .001 .14
Val/Val < Met/Met × L < R 6.478 .013 .08
Val/Met < Met/Met × L < R 6.312 .014 .07
Beta-1
F < P 14.236  < .001 .13
C < F/P 5.675 .019 .05
F > P × M > L/R 41.346  < .001 .31
C < F/P × M > L/R 4.166 .044 .04
Val/Val < Val/Met × F > P 7.416 .008 .08
Beta-2
F > P 11.097 .001 .11
C < F/P 14.704  < .001 .14
F > P × M > L/R 5.446 .022 .05
Val/Val < Val/Met × F > P 4.448 .038 .05
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Figure 3.  Topographic headmaps for each of the six spectral bands. The top row shows the grand mean 
across the three genotypes, and the lower three rows demonstrate the across-subjects means for each genotype 
separately (Val/Val, Val/Met, Met/Met). Parieto-right differences for delta and alpha-1, and right hemispheric 
differences for alpha-2 can be seen between the Met/Met genotype group and both the Val/Val and Val/Met 
genotype groups, and frontal beta-1/2 differences for Val/Met compared to Val/Val genotype groups.
Figure 4.  eLORETA source localisations for the grand mean amplitudes for each EEG band for horizontal, 
sagittal, and coronal planes. Source amplitudes are plotted as z-scores, and the scale for each band is to the right 
of the band name. L = Left; R = Right; A = Anterior; P = Posterior.
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seem to be driven by a right-parieto enhancement and a left hemispheric reduction for the Met/Met genotype 
group (see Fig. 3). This is in line with prior research that showed temporal and parieto-occipital differences 
in the Met/Met genotype  group7. eLORETA identified a series of frontal sources for delta in the superior and 
middle frontal gyrus, inferior frontal gyrus, and the anterior cingulate. Interestingly, left anterior cingulate 
abnormalities (reduced glucose metabolism and volume) have been linked to schizotypal personality disorder 
and  schizophrenia29. Further work is required to ascertain whether the left hemispheric delta reduction observed 
here in healthy young BDNF Met homozygotes is indeed linked to such left anterior cingulate abnormalities, and 
whether this confers increased psychosis  risk11. Of note, the presence of the Met allele variant has also been shown 
to have functional consequences in individuals with chronic aphasia; it may play a role in speech and language, 
which is largely laterialised. In a sample of individuals with chronic aphasia as a result of left hemisphere stroke, 
a naming task revealed a greater number of activated voxels in the right hemisphere of Val/Val homozygotes than 
Met/Met  individuals30. Future studies may seek to characterise whether healthy Met allele carriers demonstrate 
lateralised differences in speech and language processing mechanisms.
Theta amplitudes showed the typical midline frontal distribution, and this was reflected in the eLORETA 
source plots with diffuse sources in the cingulate gyrus and medial frontal gyrus. Counter to our hypothesis, 
there were no effects of genotype on theta  amplitudes4,7. One previous study reported elevated theta power in 
the Met/Met genotype group as opposed to Val/Val  homozygotes7, while another showed that theta is reduced 
in Met allele carriers during REM sleep and resting state EC  conditions4. However, these prior studies were in 
the context of depression and sleep deprivation and elicited theta amplitudes during sleep states and a memory 
task, where theta has been shown to be  maximal31. This suggests that a resting-state, eyes-open paradigm in 
healthy individuals may not be optimal to observe theta wave amplitude differences associated with BDNF rs6265.
Consistent with our hypothesis, the Met/Met genotype group exhibited reduced centro-parietal alpha-1 and 
left hemispheric alpha-2 amplitudes relative to both the Val/Val and Val/Met genotype groups. These results align 
with prior research which demonstrated that the Met/Met genotype group had reduced alpha power (8–13 Hz) 
compared to the Val/Val genotype group for temporal and parieto-occipital  regions7. eLORETA analyses matched 
the dominant alpha-1/2 midline parietal distribution, with maximal sources in the cuneus, the paracentral lob-
ule, and the postcentral gyrus. Alpha amplitudes largely originate in default mode network (DMN) functional 
hubs within the parietal and occipital  lobes32 and have been linked with inhibition of active occipital cortical 
processing. The lower alpha-1 and alpha-2 amplitudes observed here in the Met/Met genotype group may point 
to dysregulation of occipital network processing, with less deactivation of active processing in DMN occipital 
hubs during an eyes open resting  state33. Given that Met allele carriers of the BDNF Val66Met polymorphism 
have an increased risk of AD, it is important to note that reductions in alpha power (7.5–12.5 Hz) have also 
been linked to an earlier age of AD  onset34, reflecting dysregulated cortical excitability most likely associated 
with  excitotoxicity35. Future work is necessary to understand if reduced alpha power associated with the BDNF 
Val66Met polymorphism is also an early risk factor for cognitive impairment.
Our study was the first to observe greater frontal beta-1 and beta-2 amplitudes for the Val/Met genotype group 
than for the Val/Val genotype group. Prior research has revealed enhanced beta power in the Met/Met genotype 
group compared to the Val/Met genotype group (n = 13 per group), however our investigation did not replicate 
these  findings7. This may suggest an additive effect of Met allele frequency on BDNF activity and beta, although 
this is speculative and requires replication in a study with balanced genotype groups. Beta activity reflects a state 
of cortical activation via excitatory pyramidal cells mediated by inhibitory interneurons gated by γ-aminobutyric 
acid type A  (GABAA) receptors that act as ‘pacemakers’ to maintain beta and gamma  rhythms36–38, suggesting 
that Met allele carriers may have a disequilibrium of excitatory/inhibitory homeostatic inputs in these fron-
tal neural  networks39. eLORETA analysis demonstrated maximal beta-1 sources in the superior and middle 
gyrus, and maximal beta-2 sources in the superior, middle, and inferior gyrus, suggesting that these may be key 
areas of interest for future studies investigating altered  GABAA receptor expression/activity in Met allele carri-
ers, particularly in light of BDNF being shown to reduce GABA-ergic function via downregulation of  GABAA 
receptor  expression40. This relationship may be further mediated through impairment of synaptic transmission 
and plasticity in BDNF Met/Met genotypes, as prior research has demonstrated a decrease in  GABAA receptor-
mediated synaptic transmission in the pyramidal neurons of BDNF Met/Met  mice41. Future work is required 
to understand if these findings are specific to particular brain regions and if there are functional effects of this 
altered receptor status. Greater beta amplitudes observed in the Met/Met genotype group may have functional 
implications in low-arousal states, and serve as a means of compensation for impaired task performance in a state 
of low  arousal42. Although our study was conducted in a resting state, this finding could highlight a functional 
consequence of altered beta-1 and beta-2 activity in the Met-carrying groups.
Strengths, limitations, conclusion. Factors that point to increased generalisability of our study include 
a robust sample size (N = 92), and no differences in age, sex, or data recording experimental set-ups. Given that 
our sample consisted of healthy neurotypical adults, rather than individuals that are part of a clinical group, 
normative data for resting-state EO EEG is presented by our study. Additionally, we conducted eLORETA source 
localisation for each EEG band, which adds depth and breadth to our EEG spectral findings. Nevertheless, our 
study had several limitations. We chose to sum across narrow frequency bands to form each of the “classic” 
EEG bands, with the additional subdivisions of alpha-1/2 and beta-1/2. Although these band limits aligned 
with previous work, subdivision selection nonetheless remained arbitrary. Future work should seek to use a 
more data-driven approach by utilising principal components analysis (PCA) to decompose the EEG frequency 
 spectra23,43. Further, data-driven approaches such as cluster-based permutation can be applied to identify sig-
nificant clusters across both the spatial and frequency  domains44. We did not measure cognition in this cohort, 
so findings can only be interpreted in the context of intrinsic brain function. Although our study did not utilise 
9
Vol.:(0123456789)
Scientific Reports |        (2020) 10:17915  | https://doi.org/10.1038/s41598-020-74780-9
www.nature.com/scientificreports/
a clinical sample, it does provide useful insights that may pinpoint early differences in brain function at a single 
timepoint amongst (currently) neurotypical individuals, that could help predict future changes in brain function 
and disease risk; this should be researched in future longitudinal studies. Finally, our study chose to isolate the 
homozygous Met/Met group from the heterozygous Val/Met group, rather than pooling the two together as ‘Met 
allele carriers’. Although this reduced study power due to the low sample size of the Met/Met genotype group 
(n = 6), it increased our study’s comparability to existing literature that chose to isolate Met/Met separately and 
had similar genotype group sizes to  ours7,8,18,19. Obtaining a larger sample of participants who are homozygous 
for the Met allele in an effort to balance the sample size of each genotype group may further strengthen the 
power and significance of future studies. Such research would require a minimum genotype group size of 23 
to detect a moderate to large effect size similar to prior  studies7,19. From an epidemiological perspective, the 
population prevalence of Met/Met genotypes is relatively low: ~ 4.5% in prior studies, ~ 6.5% here, which would 
translate to a sample size of > 500.
This study examined the relationship between the BDNF Val66Met polymorphism and neuronal oscillatory 
activity. Findings demonstrate enhanced delta, reduced alpha-1 and alpha-2 in Met/Met homozygotes relative to 
Val allele carriers, enhanced beta-1 and beta-2 amplitudes in the Val/Met genotype group compared to the Val/
Val genotype group, and an absence of any genotypic association with theta. Our findings confirm that varied 
BDNF genotypic presentation is important in understanding resting-state EO oscillatory EEG activity in healthy, 
neurotypical adults. Findings suggested dysregulated cortical excitability/inhibition in Met allele carriers; future 
work is required to further understand these physiological mechanisms and establish an association with cog-
nition. This study highlights the importance of genetics as a factor that influences intrinsic brain activity, and 
confirms the utility of investigating genetics and neurophysiology in a neurotypical sample in future studies.
Data availability
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